Oncology
XZenith focuses on the layout of breast cancer, NSCLC and solid tumor. A comprehensive layout of the major breast cancer targets was developed.
Digestive
XZenith focuses on peptic ulcer disease. The independently developed PPI has been approved for marketing.
NASH
The product is in the clinical stage.
9th Floor, North Tower of CP Center, No.20 Jin He East Avenue,Chaoyang District,Beijing,China
Tel：010-5765 4567
Email：XZGROUP@xuanzhubio.com
Copyright © 轩竹生物科技有限公司保留所有权利 冀ICP备2020028968号-2
